MammaPrint is a 70-gene expression test used in selected people with early-stage invasive breast cancer to estimate the risk of distant recurrence. It analyzes the activity of genes in tumor tissue and classifies the cancer by genomic risk rather than relying only on tumor size, grade, lymph-node status, and receptor results. The test is best known for helping with decisions about whether adjuvant chemotherapy may be safely omitted in some patients whose clinical features suggest a higher risk but whose tumor has a low genomic risk profile.
MammaPrint is not a test for inherited breast cancer risk, and it does not look for BRCA or other germline mutations. It also does not directly detect a single actionable cancer mutation. Instead, it measures a pattern of gene activity associated with how likely the cancer is to spread to distant organs over time. The result must be interpreted with age or menopausal status, ER and HER2 status, lymph nodes, tumor size, grade, and the treatment decision being considered.
- MammaPrint analyzes the expression of 70 genes in breast tumor tissue and reports genomic recurrence risk, not inherited cancer risk.
- The core result classifies tumors as genomic Low Risk or High Risk; some reports also identify an UltraLow Risk subgroup within the low-risk range.
- A Low Risk result can support omission of chemotherapy in selected early-stage patients, but it does not mean recurrence risk is zero.
- Age matters: in MINDACT, an exploratory analysis suggested a larger chemotherapy benefit in women age 50 or younger with high clinical but low genomic risk.
- MammaPrint is most useful when the chemotherapy decision is uncertain; it should not replace ER, HER2, stage, nodal status, or other core pathology information.
Table of Contents
- What MammaPrint Measures
- Who May Benefit From MammaPrint Testing
- How the Test Is Performed
- Understanding Low, High, and UltraLow Risk Results
- Clinical Risk vs Genomic Risk
- What MammaPrint Can and Cannot Say About Chemotherapy
- Limitations, Common Questions, and Next Steps
What MammaPrint Measures
MammaPrint measures patterns of gene expression that are associated with the likelihood of distant breast cancer recurrence. It is a prognostic genomic assay performed on the tumor itself. The 70 genes reflect processes such as cell proliferation, invasion, metastasis, and other aspects of tumor biology.
Gene expression is different from a DNA mutation test. A mutation panel asks whether the DNA sequence contains specific alterations such as PIK3CA or ESR1. MammaPrint instead measures messenger RNA activity across a defined set of genes and combines the pattern into a genomic risk classification.
The result adds biological information to standard pathology. Traditional risk assessment already uses:
- tumor size;
- lymph-node involvement;
- histologic grade;
- estrogen receptor and progesterone receptor status;
- HER2 status;
- age and menopausal status;
- other clinical features.
A genomic assay can be most helpful when these factors do not give a clear answer about the expected value of chemotherapy. The broader breast cancer biomarker panel explains why genomic prognosis tests answer a different question from ER, PR, HER2, and mutation testing.
MammaPrint should not be confused with hereditary testing. A patient with a MammaPrint Low Risk tumor could still carry a germline BRCA1, BRCA2, PALB2, or other pathogenic variant if personal or family history indicates inherited susceptibility. Conversely, a MammaPrint High Risk result does not prove that the cancer is hereditary.
Who May Benefit From MammaPrint Testing
MammaPrint is mainly used in early-stage invasive breast cancer when adjuvant chemotherapy is being considered and the expected benefit is uncertain. The strongest clinical utility data come from patients with hormone receptor-positive, HER2-negative disease, including selected node-negative cancers and cancers with one to three positive lymph nodes.
The large MINDACT trial enrolled patients with operable early breast cancer and up to three positive lymph nodes. It compared clinical risk with genomic risk from the 70-gene signature. This design is important because MammaPrint is most useful when the two forms of risk assessment do not agree.
Under current ASCO guidance, MammaPrint may be used in appropriately selected postmenopausal patients or patients older than 50 with ER-positive/HER2-negative early breast cancer that is node-negative or has one to three positive nodes. Use in younger or premenopausal patients requires greater caution because chemotherapy may provide benefit that is not fully captured by the genomic classification.
The test is generally not used to guide adjuvant treatment for HER2-positive or triple-negative breast cancer. Those subtypes have treatment pathways driven by HER2-targeted therapy, immunotherapy, chemotherapy sensitivity, and other validated factors. Before a genomic recurrence assay is interpreted, the estrogen receptor result and HER2 status should be firmly established.
Testing is also less likely to add value when the clinical decision is already obvious. If a tumor has very low clinical risk and chemotherapy would not be recommended regardless of the genomic result, the assay may not change management. At the other extreme, if chemotherapy is clearly indicated because of extensive nodal disease or another high-risk feature outside the validated use of the assay, MammaPrint may not resolve the decision.
How the Test Is Performed
MammaPrint is performed on breast cancer tissue that has already been removed during biopsy or surgery, so it usually does not require another procedure. The laboratory isolates RNA from the tumor and measures the activity of the 70-gene signature.
No fasting, medication change, or special patient preparation is needed. What matters is whether the pathology specimen contains enough suitable invasive tumor. The test can be performed on commonly used formalin-fixed, paraffin-embedded tissue in current clinical workflows.
The ordering process usually follows these steps:
- The oncology team confirms that the patient’s stage, receptor profile, nodal status, and treatment question fit a setting where genomic testing could be useful.
- A pathologist identifies an appropriate tumor block or tissue section.
- The specimen is sent or processed according to the test laboratory’s requirements.
- RNA expression is analyzed and converted into a genomic risk result.
- The oncologist combines that result with clinical risk and patient factors before recommending adjuvant therapy.
Turnaround time varies by laboratory and shipping logistics. Because the result may influence a chemotherapy decision, testing is typically ordered soon after definitive pathology is available rather than months later.
MammaPrint is a different type of assay from Oncotype DX, which uses a 21-gene Recurrence Score with its own evidence base and decision thresholds. Results from one assay should not be converted into the other assay’s score categories.
Understanding Low, High, and UltraLow Risk Results
The most important MammaPrint distinction is whether the tumor is classified as genomic Low Risk or High Risk. The report may also provide a numerical MammaPrint Index and may identify an UltraLow Risk category within the low-risk range.
| Result | General meaning | What it does not mean |
|---|---|---|
| UltraLow Risk | Very indolent genomic profile associated with exceptionally low long-term distant recurrence risk in studied populations | It does not guarantee zero recurrence or automatically justify stopping all endocrine therapy |
| Low Risk | Genomic pattern associated with a lower risk of distant recurrence | It does not mean chemotherapy can always be omitted, especially in younger patients or higher clinical-risk settings |
| High Risk | Genomic pattern associated with a higher risk of distant recurrence | It does not prove chemotherapy will work or specify which chemotherapy regimen is best |
What UltraLow Risk means
The UltraLow threshold identifies a subset of tumors with particularly indolent biology. Long-term studies have shown very low distant recurrence rates in this group, including older patients. The result may become relevant when discussing the intensity or duration of adjuvant therapy, but it should be used carefully because age, competing health risks, endocrine therapy tolerance, and the evidence for the specific decision still matter.
A 2024 analysis from the NSABP B-42 trial also studied MammaPrint risk categories in relation to extended letrozole therapy. Such research may refine how genomic risk is used for long-term endocrine decisions, but MammaPrint should not be treated as a universal yes-or-no test for extended endocrine therapy in every patient.
The Breast Cancer Index has a separate evidence base for questions about late recurrence and extended endocrine therapy. Using the right assay for the right clinical question is more important than simply ordering more genomic tests.
Clinical Risk vs Genomic Risk
MammaPrint is especially valuable when clinical risk and genomic risk are discordant. Clinical risk comes from features such as tumor size, grade, age, nodal involvement, and hormone-receptor status. Genomic risk comes from the 70-gene expression pattern.
There are four conceptual combinations:
- Low clinical risk + low genomic risk: both approaches suggest a favorable prognosis.
- High clinical risk + high genomic risk: both approaches suggest a higher risk, making chemotherapy more likely to be recommended when otherwise appropriate.
- High clinical risk + low genomic risk: the tumor looks concerning by traditional features but biologically lower risk by the gene signature. This was the most important de-escalation group in MINDACT.
- Low clinical risk + high genomic risk: traditional features are favorable, but the genomic profile is higher risk. The clinical value of changing treatment solely because of this discordance is less straightforward in some settings.
In MINDACT, patients with high clinical risk but low genomic risk who did not receive chemotherapy had excellent five-year distant metastasis-free survival. With longer follow-up, the absolute chemotherapy benefit in the randomized high-clinical/low-genomic group remained modest overall.
However, age changed the interpretation. In an exploratory hormone receptor-positive/HER2-negative analysis, women age 50 or younger had an estimated 5.0 percentage-point difference in eight-year distant metastasis-free survival favoring chemotherapy, whereas women older than 50 had almost no absolute difference. The younger-patient finding may partly reflect ovarian function suppression caused by chemotherapy rather than a purely cytotoxic effect. This is one reason a Low Risk result should not be used to automatically omit chemotherapy in a premenopausal patient.
What MammaPrint Can and Cannot Say About Chemotherapy
MammaPrint can help estimate whether the expected absolute benefit of chemotherapy is small enough to consider omission in a validated population, but it is not a direct chemotherapy-sensitivity test. This distinction is critical.
A Low Risk result supports the idea that distant recurrence risk is low enough that chemotherapy may add little absolute benefit in some patients. That is different from proving the tumor is biologically resistant to chemotherapy. A High Risk result identifies a population with greater recurrence risk, but it does not guarantee that chemotherapy will prevent recurrence.
Recent real-world analyses from the FLEX Registry have explored MammaPrint as a continuous measure rather than only a binary high/low result. These studies suggest that the degree of genomic risk may contain additional information about chemotherapy benefit and even about benefit from anthracycline-containing regimens. These findings are clinically interesting, but they should be integrated with established guidelines and prospective evidence rather than treated as universal rules.
A sound chemotherapy discussion should include:
- the absolute recurrence risk without chemotherapy;
- the expected absolute benefit from chemotherapy;
- age and menopausal status;
- number of involved lymph nodes;
- tumor size and grade;
- ER, PR, and HER2 status;
- medical conditions that increase chemotherapy risk;
- fertility and ovarian-function considerations;
- patient preferences about small potential benefits versus toxicity.
The result is therefore a decision aid, not a verdict. Two patients with the same MammaPrint category can reasonably make different treatment choices because their clinical risk and priorities differ.
Limitations, Common Questions, and Next Steps
MammaPrint is useful only within the populations and treatment questions supported by evidence. It cannot answer every recurrence or therapy question in breast cancer.
Does Low Risk mean the cancer will not return?
No. Low genomic risk means the probability of distant recurrence is lower in studied populations. Local recurrence, new primary breast cancers, and distant recurrence can still occur. Endocrine therapy, radiation, surgery, and appropriate follow-up remain important when indicated.
Does High Risk mean chemotherapy is mandatory?
No. High Risk strengthens the rationale for systemic treatment but does not erase age, health, comorbidities, competing risks, or patient preference. Some people cannot safely receive standard chemotherapy, and others may have clinical features that change the expected benefit.
Can the test be repeated later?
MammaPrint is generally intended to characterize the primary early-stage tumor for an adjuvant treatment decision. It is not usually repeated serially like a blood tumor marker. If metastatic disease develops, current ER, HER2, and actionable mutation testing usually becomes more relevant than repeating the original genomic recurrence assay.
Is the numerical index the same as a recurrence percentage?
No. The MammaPrint Index is part of the assay’s genomic classification. It should not be read as a literal percentage chance of recurrence. Ask the oncology team to translate the category into the absolute risk and treatment benefit that apply to your age, stage, nodal status, and receptor profile.
What should you ask before ordering it?
Useful questions include:
- Is my cancer in a group where MammaPrint has validated clinical utility?
- Am I clinically low risk or high risk, and how was that determined?
- Would a Low Risk result actually change the chemotherapy recommendation?
- How does my age or menopausal status affect the meaning of a Low Risk result?
- Are one to three positive lymph nodes present, and how does that alter the decision?
- Would another genomic assay be better validated for my exact situation?
- Will insurance coverage or tissue availability affect the testing plan?
The best use of MammaPrint is targeted: order it when the answer could resolve a real treatment uncertainty, then interpret the genomic result alongside the clinical risk rather than in place of it.
A practical way to frame the consultation is to ask for two numbers: the estimated risk of distant recurrence with the planned endocrine therapy and the estimated absolute reduction that chemotherapy might add. The genomic category helps inform those estimates, but it does not replace them. This keeps the decision focused on expected benefit rather than on whether a report uses reassuring or alarming terminology.
MammaPrint is also not designed as a serial monitoring test. Repeating the assay during follow-up does not show whether microscopic disease is shrinking or whether a recurrence is developing. After the original adjuvant-treatment decision, routine follow-up relies on clinical assessment and standard breast cancer surveillance. If a new lesion or recurrence appears, it requires its own pathology and biomarker evaluation rather than a comparison with the old genomic risk category.
References
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update 2022 (Guideline)
- 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age 2021 (RCT)
- Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study 2022
- Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial 2024
- MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data 2025
- Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study 2026
Disclaimer
This article is for general education and does not replace personalized oncology advice. MammaPrint should be ordered and interpreted in the context of age, menopausal status, tumor stage, lymph nodes, receptor status, health conditions, and current treatment guidelines. Do not start, omit, or change chemotherapy or endocrine therapy based on a genomic risk result without discussing the complete case with your oncology team.
